[Research Report] The tissue engineering market is expected to reach US$ 13,236.87 million in 2022 and is projected to touch US$ 29,659.93 million by 2028. It is expected to grow at a CAGR of 12.2% from 2022 to 2028.

Tissue engineering is a biomedical engineering discipline that uses a combination of cells, engineering, material methods, and appropriate biochemical and physicochemical factors to regenerate, preserve, enhance, or replace various types of biological tissues. Tissue Engineering (TE) is a rapidly evolving discipline that aims to repair, replace, or regenerate tissues or organs by converting fundamental physics, chemistry, and biology knowledge into practical and effective materials or devices and clinical strategies.

Tissue engineering has several primary functions in medicine and research: Assisting in tissue or organ repair, including bone repair (calcified tissue), cartilage tissue, heart tissue, pancreatic tissue, and vascular tissue. The field also researches the behavior of stem cells. Stem cells can develop into many different cell types and help repair areas of the body. The 3D nature of tissue engineering allows the study of tumor architecture in a more detailed environment. It also provides an environment to test potential new drugs for these diseases. Growth in the number of R&D activities with increasing awareness of tissue engineering in emerging markets is expected to support the market growth. Developed nations have adopted technological advances in tissue engineering and regenerative medicine that contribute to expanding the global tissue engineering market

The scope of the global tissue engineering market includes material type, application, and geography. The market for tissue engineering is analyzed based on regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The report offers insights and in-depth analysis of the global tissue engineering market emphasizing on various parameters such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the globe.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Tissue Engineering Market: Strategic Insights

Tissue Engineering Market

• 
  CAGR (2022 - 2028)

  12.2%
• Market Size 2022
  US$ 13.24 Billion
• Market Size 2028
  US$ 29.66 Billion

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• Stryker Corporation
• Organogenesis Inc.
• Cook Biotech Inc.
• Integra Life Sciences Corporation
• 3M
• AbbVie Inc.
• Medtronic
• Zimmer Biomet
• Baxter International Inc.

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Material Type

• Synthetic Material
• Biologically Derived Materials
• Others

Application

• Orthopedic
• Musculoskeletal & Spine
• Neurology
• Cardiology & Vascular
• Skin & Integumentary
• Urology
• GI & Gynecology
• Cancer
• Others

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Insights

Increasing Number of Road Accidents and Trauma Injuries, and Elevating Incidence of Chronic Diseases

The rising incidence of chronic diseases and increasing number of trauma injuries and road accidents are prime factors contributing to the market's growth for advanced treatment procedures, such as tissue engineering. Road accidents are among the major fatalities worldwide as they cause serious injuries to bones and organs. As per the WHO, ~20–50 million people get injured every year in road accidents. Tissue engineering offers alternatives to surgical reconstruction, transplantation, and mechanical device instruction to repair damaged tissues. The global tissue engineering market is mainly driven by a continuous need for effective regenerative treatments to treat increasing cases of diabetes, obesity, and other disorders caused by lifestyle changes, expanding geriatric population, and a rising number of trauma cases.

A spinal cord injury (SCI) refers to damage to the spinal cord that temporarily or permanently changes its function. According to the Multidisciplinary Digital Publishing Institute (MDPI), an estimated 3 million people live with traumatic SCI worldwide, with approximately 180,000 new cases reported each year. SCI often results in devastating, long-lasting neurological deficits, manifesting as dysfunction of the motor, sensory, or autonomic nervous systems below the level of injury. To thoroughly repair or regenerate damaged tissues or organs and restore their functions has been a dream of humans. The advent of Tissue Engineering and Regenerative Medicine (TERM) seems to make this possible. Tissue engineering combines cells, scaffolds, and growth factors to regenerate tissue or replace damaged or diseased tissue.

Cancer is among the leading causes of mortality worldwide, and the disease affects a huge population. Therefore, it acts as a huge financial burden on society. According to the WHO, in 2018, ~9.6 million deaths occurred due to cancer globally. However, growing research on developing effective treatments for the disease is positively impacting the market growth. Gene therapy and cell therapy are transforming the cancer treatment landscape; for example, Novartis Kymriah is used to treat diffuse large B-cell lymphoma. The launches of more such products would drive the demand for cell and gene therapy, thus fueling the global tissue engineering market in the coming years.

Material Type-Based Insights                            

Based on material type, the global tissue engineering market is segmented into synthetic material, biologically derived materials, and others. In 2022, the biologically derived materials segment is expected to lead the market. A biomaterial plays a significant role in the development of tissue engineering and biomedical devices that naturally increase the regenerative potential of tissues to restore body mechanism, in a state of deterioration. Biologically derived materials are used in creating neo-tissues in vitro that are identical to their fundamental body parts. These materials also help in tissue regeneration by a controlled presentation and on-demand release of specific chemokines at sites of injury, tissue-resembling structural, temporary biodegradable support matrices with natural and functional characteristics. However, the synthetic material segment is likely to register highest CAGR in the global tissue engineering market during the forecast period.

Application-Based Insights

Based on application, the global tissue engineering market is segmented into orthopedic, musculoskeletal & spine, neurology, cardiology & vascular, skin & integumentary, urology, GI & gynecology, cancer, and others. The orthopedic, musculoskeletal & spine segment is expected to lead the market in 2022. However, the skin & integumentary segment is anticipated to register the highest CAGR in the market during the forecast period.

Ever since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a public health emergency of international concern in late January 2020, medical professionals and researchers have been urging the need for comprehensive and rapid testing of citizens to plan measures that can contain the spread of the virus. COVID-19 pandemic has become the most significant challenge across the world. This challenge was frightening especially in developing countries across the globe as it will lead to reducing imports due to disruptions in global trade. Till date no definitive treatment against COVID 19 has been established. Hence, lack of definitive therapy offers significant opportunities for tissue engineering market as US FDA has recently approved use of plasma therapy for critically ill COVID 19 patients. Over time, real-time polymerase chain reaction tests and antibody tests have emerged as vital techniques for the global healthcare system to manage the outbreak. The supply chain disruptions, along with the enormous demand for effective diagnostics as well as therapeutics for the treatment of COVID 19 had put healthcare research industry in critical situation in various regions. Risks were majorly on emerging markets that face healthcare constraints and tighter financial conditions. The COVID-19 pandemic also hampered clinical trials, drug development, and the diagnostics industry's operation in the region. Also, significant disruptions to routine research activities involving tissue engineering and regenerative medicines were also observed due to the COVID-19 pandemic. A lot of industries had been affected by the crisis including tissue engineering research activities due to shutdown of research centers, lack of healthcare facilities, and increasing number of cases. However, after the establishment of COVID-19 vaccine, the research centers have commenced the studies and research on stem cells, regenerative medicine, and other therapies. Hence, the tissue engineering market in Europe is gaining attention after the COVID-19 impact.

Companies in this market commonly adopt product launches and expansion strategies to expand their footprint worldwide and meet the growing demand. Product innovation is one of the popular strategies companies take up to cater to dynamic customer demand worldwide, which also lets players maintain their brand name globally.

In April 2022, Organogenesis Inc. announced that the latest advanced wound care research on its PuraPly AM, Affinity, Apligraf, NuShield, Novachor, and Organogenesis Physician Solutions product lines, which was showcased at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference held April 6-10, 2022, in Phoenix, Arizona.

In July 2021, Integra LifeSciences Holding Corporation announced positive clinical outcomes for PriMatrix Dermal Repair Scaffold to manage hard-to-heal diabetic foot ulcers (DFUs).

Tissue Engineering Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

 

Tissue engineering – Market Segmentation

The global tissue engineering market is analyzed on the basis of material type and application. Based on material type, the market is further segmented into synthetic material, biologically derived materials, and others. Based on application, the market is segmented into orthopedic, musculoskeletal & spine, neurology, cardiology & vascular, skin & integumentary, urology, GI & gynecology, cancer, and others. By geography, the market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and the Rest of the  MEA), and South & Central America (Brazil, Argentina, and the Rest of SAM).

Company Profiles

• Stryker Corporation
• Organogenesis Inc.
• Cook Biotech Inc.
• Integra Life Sciences Corporation
• 3M
• AbbVie Inc.
• Medtronic
• Zimmer Biomet
• Baxter International Inc.
• DePuy Synthes (Johnson & Johnson Services, Inc.)
• B. Braun Melsungen AG